...is planning a Phase 3 trial to test whether its diabetes drug, Rybelsus, can prevent early-stage development of dementia in Alzheimer's patients. The trial will begin in the first half of 2021. In previous research, Novo found that of 16,000 senior diabetes patients, only 15 that received Rybelsus ever developed dementia. For the treatment of type 2 diabetes, Rybelsus currently holds preferred status under the pharmacy benefit for 38% of all covered lives.
SOURCE: MMIT Analytics, as of 12/17/20
No comments:
Post a Comment